Mark Flory Email and Phone Number

Optimized mass spectrometry equipment, including multiple liquid chromatography instruments, a hybrid hybrid Orbitrap mass spectrometer and a triple quadrupole mass spectrometer, for discovery and validation of protein expression patterns in various sample typesDeveloped and refined protocols for wet lab sample preparation, and implemented quality control standards to ensure consistency and robustness of analysesContributed significantly to laboratory organization by implementing formal systems for project management, capturing and unifying SOPs, organizing laboratory samples, and sample tracking

Oversaw installation and implementation all equipment necessary and software for in-house mass spectrometry platform including multiple liquid chromatography instruments, two Thermo LTQ-Orbitrap VelosPro hybrid mass spectrometry instruments, Waters G2-S Xevo Q-TOF instrumentDeveloped methods for preparing enriched protein samples from primary tumors for shotgun-based proteomic (LC-MS/MS) interrogation and for top-down, intact mass measurements of antibodies and ADCs; greater than 2000 samples for target discovery analyzed by in-house LC-MS/MS over approximately three-year timespanEstablished pipeline and implemented necessary software for computational spectral matching, quantitation, and deconvolution and contributed significantly to evolving systems for tracking, organizing and mining sample-associated datasetsDeveloped, in concert with Igenica Histo-Pathology Group, novel methods for proteomic profiling of histologically-selected portions of primary tumor and normal comparator specimens and patient-derived xenografts enriched for cell types of interestInnovated new methods for analysis of antibody drug conugate (ADC) adduct species and modified substructures using a combination of top-down and shotgun-based mass spectrometry leveraging multiple instrumentsContributed to the target selection process, multiple business development activities, IND documentation, and numerous due diligence activitiesDelivered oral presentation entitled “Target Identification for Oncology-Directed Antibody and ADC Therapeutics” at 2014 Peptalk Conference, Palm SpringsInvited Presenter for Hason-Wade World ADC Summit Workshop "Deep and Extensive Characterization of Antibody Drug Conjugates (ADCs) by Liquid Chromatography and Mass Spectrometry" - October 2014, San Diego

Developed proteomic methods, including antibody-based and other affinity strategies, for isolation of transcription factor complexes from plants for determination of candidate binding partners; in multiple cases, sought-after targets were successfully identified via mass spectrometry, in addition to both known and novel candidate protein interactorsPioneered and implemented chromatin immunoprecipitation (ChIP) platform for determining protein-DNA interactions in-vivo in plants at Mendel including development of all wet-lab techniques, implementation of in-house deep sequencing (Illumina) technologies, and evaluation and application of analytical software to extract data from resulting global ChIP-Seq datasetsAwarded the second-ever Mendel Somerville Research Award recognizing significant scientific contributions at Mendel Biotechnology, specifically in this case for successful development and application of the ChIP-Seq platformManaged and performed quality-control analyses, including Western blotting and immunoprecipitation assays, of novel, newly-generated antibodies directed against proteins of interest for use in in-vitro and global in-vivo affinity-based assaysSelected to attend 21st International Conference on Arabidopsis Biology in Yokohama, Japan (June 2010) to document recent scientific and technological developments with potential application for efforts at MendelCo-authored multiple research reports detailing scientific findings to Mendel corporate partners Prepared and delivered formal research talks to Mendel scientists and management, to Mendel’s Scientific Advisory Board composed of leading academic plant researchers from around the world, and to Mendel’s corporate partnersAwarded Sommerville Research Award for contributions to platform development at Mendel.

Established and ran an independent research laboratory employing multidimensional affinity chromatography and tandem mass spectrometry as a discovery tool in multiple biological contexts Ran and maintained institutional ThermoFisher LCQ Deca XP tandem mass spectrometer for electrospray ionization-based peptide identification, and associated Agilent Binary 1100 HPLC system for reversed-phase separation of analytes Supervised the research projects of postdoctoral, doctoral and undergraduate researchers in the laboratory with various projects characterizing the biological function of chromosome-associated proteins identified by mass spectrometry Engaged in collaborative proteomic (mass spectrometric) analysis of samples including analyses of hemoglobin protein structure (Mukerji Group, Wesleyan), function of yeast oncogene homologues (Cande Group, UC Berkeley), and interactions of signal transduction components (Measday Group, UBC Vancouver) Designed and taught graduate and undergraduate courses across the departmental curriculum full-time, and performed administrative/committee duties as necessary Delivered oral presentation at Fourth International Fission Yeast Meeting, Copenhagen, Denmark (Summer 2007)

Used affinity purification techniques and tandem mass spectrometry to identify a novel protein associated with chromosome ends; characterized this protein's biological function using molecular genetics and fluorescence microscopy Applied a reverse chemical genetics approach using tandem mass spectrometry to identify the protein target of a mitotically active diterpenoid purified from a natural compound extract (with Roberge Group, UBC Vancouver) Employed chemical labeling technology and tandem mass spectrometry to quantitatively assess for the first time in any eukaryote global proteome expression patterns during full, synchronized cell cycle transit Developed integrated proteomic, microarray and translation state array analysis to simultaneously assess gene expression (with Morris Group, U. Washington, Seattle) Contributed to the development of Peptide Atlas databases for downstream bioinformatic analysis of existing proteomic data and for identification of "proteotypic" peptides as potential biomarkers